Table 1 Patient Demographics and Characteristics

Age (median, min-max)

56 (35–71)

43 (24–60)

47.5 (24–71)

0.005

Ethnicity

–

–

–

0.028

Hispanic or Latino

7 (36.8%)

1 (5.9%)

8 (22.2%)

–

Not Hispanic or Latino

11 (57.9%)

16 (94.1%)

27 (75.0%)

–

Not Reported

1 (5.3%)

0 (0.0%)

1 (2.8%)

–

Race

–

–

–

0.597

Black or African American

3 (15.8%)

4 (23.5%)

7 (19.4%)

–

White

14 (73.7%)

13 (76.5%)

27 (75.0%)

–

Not Reported

2 (10.5%)

0 (0.0%)

2 (5.6%)

–

Performance status

–

–

–

0.717

0

13 (68.4%)

13 (76.5%)

26 (72.2%)

–

1

6 (31.6%)

4 (23.5%)

10 (27.8%)

–

Histology

–

–

–

0.493

Adenocarcinoma NOS

4 (21.1%)

1 (5.9%)

5 (13.9%)

–

Adenosquamous

1 (5.3%)

2 (11.8%)

3 (8.3%)

–

Squamous Cell Carcinoma

14 (73.7%)

14 (82.4%)

28 (77.8%)

–

FIGO stage

–

–

–

0.988

IB

3 (15.8%)

3 (17.6%)

6 (16.7%)

–

IIB

12 (63.2%)

10 (58.8%)

22 (61.1%)

–

IIIB

3 (15.8%)

4 (23.5%)

7 (19.4%)

–

IVA

1 (5.3%)

0 (0.0%)

1 (2.8%)

–

Baseline PET/CT SUV max for cervix (median, min -max)

18.85 (5.1−36)

16.5 (8.4–35.9)

18.3 (5.1–36)

0.75

Missing

1

0

1

–

Para-aortic lymph node metastases (PET/CT)

–

–

–

0.482

No

7 (36.8%)

10 (58.8%)

17 (47.2%)

–

Yes

9 (47.4%)

5 (29.4%)

14 (38.9%)

–

Not available

3 (15.8%)

2 (11.8%)

5 (13.9%)

–

Pre-treatment PD-L1 (SP263) immune score

–

–

–

0.588

Median (min – max)

3 (0–40)

1 (0.5–5)

2.5 (0–40)

–

Negative ( < 1%)

2 (10.5%)

3 (17.6%)

5 (13.9%)

–

Positive ( ≥ 1%)

8 (42.1%)

9 (52.9%)

17 (47.2%)

–

missing

9 (47.4%)

5 (29.4%)

14 (38.9%)

–

Pre-treatment PD-L1 (SP263) tumor cell score

–

–

–

0.023

Median (min – max)

0.5 (0–95)

12.5 (0.5–100)

1 (0–100)

–

Negative ( < 1%)

7 (36.8%)

2 (11.8%)

9 (25.0%)

–

Positive ( ≥ 1%)

3 (15.8%)

10 (58.8%)

13 (36.1%)

–

missing

9 (47.4%)

5 (29.4%)

14 (38.9%)

–